NIAID begins enrolling volunteers for Phase IIB study of Merck's vaccine.
D016915:AIDS Vaccines / Q000008:administration & dosage*; D000256:Adenoviridae / Q000235:genetics; D004345:Drug Industry; D005814:Genes, Viral; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D009316:National Institutes of Health (U.S.); D014481:United States; D019562:Viral Load
D016915:AIDS Vaccines